Rapid Influenza Diagnostic Tests Market to cross $689 million by 2025: Global Market Insights, Inc.
September 10, 2019 07:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Sept. 10, 2019 (GLOBE NEWSWIRE) -- U.S. rapid influenza diagnostic tests market was valued at USD 130.5 million in 2018 and is estimated to witness substantial amount of...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
August 28, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
August 21, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
August 15, 2019 17:37 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Vaccines Market value to hit $72.5 billion by 2025: Global Market Insights, Inc.
August 15, 2019 02:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Global Market Insights, Inc., announces a research report on ‘Vaccines Market Trends and Forecast 2019-2025’. The report covers an extensive...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
August 05, 2019 16:15 ET
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...
Novan SB206 Phase 3 Molluscum Pivotal Program Update
July 11, 2019 08:15 ET
|
Novan, Inc.
More than 50 percent of total expected patients now enrolledVirtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity ...
Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients
July 10, 2019 09:30 ET
|
Relevium Technologies Inc
MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an...
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
July 08, 2019 08:00 ET
|
Bellicum Pharmaceuticals, Inc.
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
June 26, 2019 04:00 ET
|
Relevium Technologies Inc
MONTREAL, June 26, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or...